Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 6;11:149. doi: 10.3389/fneur.2020.00149

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Abdullah, Crawford, Tsolaki, Börjesson-Hanson, Olde Rikkert, Pasquier, Wallin, Kennelly, Ait-Ghezala, Paris, Hendrix, Blennow, Lawlor and Mullan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cerebrospinal fluid tau biomarkers. Total tau and P181Tau levels were increased in nilvadipine-treated moderate AD patients compared to their respective placebo groups. (Mean ± SE n = 9 for moderate AD on nilvadipine, n = 12 for moderate AD on placebo, n = 14 for mild AD on nilvadipine, n = 20 for mild AD on placebo). Levels of (A) total tau and (B) P181 tau were increased in moderate AD subjects treated with nilvadipine. In mild AD subjects, total tau or P181 tau did not differ between nilvadipine-treated and placebo control groups.*p < 0.05.